AMPX

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · derivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,174,051

Underlying: Common stock · 109,800 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.87 to $3, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000007 · wk-form4_1709850983.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,283,851

Underlying: Common stock · 150,000 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.04 to $4.58, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000005 · wk-form4_1707347184.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · derivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,433,851

Underlying: Common stock · 150,000 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.96 to $5.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,366

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.96 to $4.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-24-000003 · wk-form4_1704407560.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 150,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001628280-23-041705 · wk-form4_1702683526.xml · nonDerivative · entry 3

Amprius, Inc. · CIK 0001946058 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,215,552

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 6

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,785,000

F6 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.53 to $3.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 5

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,067,142

F6 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.53 to $3.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-041705 · wk-form4_1702683526.xml · nonDerivative · entry 2

Amprius, Inc. · CIK 0001946058 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,315,552

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.48 to $3.69, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 4

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,870,000

F5 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.89, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 3

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,237,142

F5 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.89, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-041705 · wk-form4_1702683526.xml · nonDerivative · entry 1

Amprius, Inc. · CIK 0001946058 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,415,552

F1 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.54 to $3.73, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 2

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,900,000

F3 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.705 to $3.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041626 · wk-form4_1702595211.xml · nonDerivative · entry 1

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,297,142

F1 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.95, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 6

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,920,000

F7 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 5

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,337,142

F6 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.82 to $4.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 9

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,583,851

Underlying: Common stock · 54,477 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.93, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 4

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,930,000

F5 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 3

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,357,142

F5 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.93 to $4.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 8

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,638,328

Underlying: Common stock · 47,767 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.91 to $4.135, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,767

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 2

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,940,000

F3 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-041100 · wk-form4_1701994778.xml · nonDerivative · entry 1

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,377,142

F1 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.54, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · derivative · entry 7

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,686,095

Underlying: Common stock · 47,756 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.12 to $4.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000010 · wk-form4_1701992332.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 6

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,950,000

F8 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.99 to $4.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 5

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,397,142

F7 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $4.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 4

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,965,000

F6 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.63 to $4.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 3

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,427,142

F6 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.63 to $4.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 2

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,985,000

F3 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.58 to $3.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4 · balance_after: Includes 1,000,000 shares previously held through Justin E. Mirro 2020 Qualified Annuity Trust dated 6/27/20, which were transferred on September 13, 2023 to Kensington Capital Trust dated 6/27/20.

F5 · ownership.nature: The shares are owned by Elizabeth Mirro as trustee of the Kensington Capital Trust dated 6/27/20. Elizabeth Mirro is the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.

SEC source: 0001628280-23-040389 · wk-form4_1701388158.xml · nonDerivative · entry 1

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,467,142

F1 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $4.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · derivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,733,851

Underlying: Common stock · 27,631 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.76 to $4.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000008 · wk-form4_1700603388.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 9

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,761,482

Underlying: Common stock · 49,508 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.72 to $3.08, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 8

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,810,990

Underlying: Common stock · 48,052 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,052

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.